PE20230444A1 - Anticuerpos - Google Patents
AnticuerposInfo
- Publication number
- PE20230444A1 PE20230444A1 PE2022001942A PE2022001942A PE20230444A1 PE 20230444 A1 PE20230444 A1 PE 20230444A1 PE 2022001942 A PE2022001942 A PE 2022001942A PE 2022001942 A PE2022001942 A PE 2022001942A PE 20230444 A1 PE20230444 A1 PE 20230444A1
- Authority
- PE
- Peru
- Prior art keywords
- antibodies
- antigen
- nucleic acid
- binding region
- cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente invencion se refiere a anticuerpos biespecificos que comprenden una region de union a antigeno que se puede unir al inhibidor 1 de la activacion de celulas T que contiene el dominio V-set o VTCN1 (B7H4) y una region de union a antigeno que se une a CD3. Tambien se refiere a una composicion farmaceutica, un acido nucleico, una celula que comprende un acido nucleico, un metodo de produccion del anticuerpo y un kit de partes. Dichos anticuerpos son utiles en el diagnostico y tratamiento del cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20164059 | 2020-03-18 | ||
PCT/EP2021/056879 WO2021185934A1 (en) | 2020-03-18 | 2021-03-17 | Antibodies binding to b7h4 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20230444A1 true PE20230444A1 (es) | 2023-03-08 |
Family
ID=69846241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022001942A PE20230444A1 (es) | 2020-03-18 | 2021-03-17 | Anticuerpos |
Country Status (19)
Country | Link |
---|---|
US (3) | US20210292418A1 (es) |
EP (1) | EP4121456A1 (es) |
JP (1) | JP2023517753A (es) |
KR (1) | KR20220154757A (es) |
CN (1) | CN115298221A (es) |
AR (1) | AR121599A1 (es) |
AU (1) | AU2021236906A1 (es) |
BR (1) | BR112022015572A2 (es) |
CA (1) | CA3168613A1 (es) |
CL (1) | CL2022002494A1 (es) |
CO (1) | CO2022014603A2 (es) |
CR (1) | CR20220521A (es) |
DO (1) | DOP2022000181A (es) |
EC (1) | ECSP22080714A (es) |
IL (1) | IL296362A (es) |
MX (1) | MX2022009936A (es) |
PE (1) | PE20230444A1 (es) |
TW (1) | TW202200624A (es) |
WO (1) | WO2021185934A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20230444A1 (es) | 2020-03-18 | 2023-03-08 | Genmab As | Anticuerpos |
CA3207652A1 (en) | 2021-03-26 | 2022-09-29 | Stephanie Cornen | Cytokine anchors for nkp46-binding nk cell engager proteins |
EP4334359A1 (en) * | 2021-05-07 | 2024-03-13 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3 |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
EP4352098A1 (en) | 2021-06-09 | 2024-04-17 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
CN116867805A (zh) * | 2021-09-27 | 2023-10-10 | 盛禾(中国)生物制药有限公司 | 一种异源二聚体蛋白质及其应用 |
GB202202171D0 (en) * | 2022-02-17 | 2022-04-06 | Bivictrix Ltd | Novel methods of therapy |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
CA2361421A1 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
AU2003209446B2 (en) | 2002-03-01 | 2008-09-25 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
ES2442615T5 (es) | 2002-07-18 | 2023-03-16 | Merus Nv | Producción recombinante de mezclas de anticuerpos |
JP5026072B2 (ja) | 2003-07-01 | 2012-09-12 | イミューノメディクス、インコーポレイテッド | 二重特異性抗体の多価キャリヤー |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007059782A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
CN103073639A (zh) | 2006-03-17 | 2013-05-01 | 比奥根艾迪克Ma公司 | 稳定的多肽组合物 |
PL1999154T3 (pl) | 2006-03-24 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe |
AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
CN101821288A (zh) | 2007-06-21 | 2010-09-01 | 宏观基因有限公司 | 共价双抗体及其用途 |
US8629246B2 (en) | 2007-09-26 | 2014-01-14 | Ucb Pharma S.A. | Dual specificity antibody fusions |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
AR069747A1 (es) | 2007-11-30 | 2010-02-17 | Medarex Inc | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
CA2709847C (en) | 2008-01-07 | 2018-07-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
KR20110112301A (ko) | 2008-11-18 | 2011-10-12 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
SG172254A1 (en) | 2008-12-19 | 2011-07-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
US20120134993A1 (en) | 2009-03-27 | 2012-05-31 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
JP6184695B2 (ja) | 2009-12-04 | 2017-08-23 | ジェネンテック, インコーポレイテッド | 多重特異性抗体、抗体アナログ、組成物、及び方法 |
PL2542256T3 (pl) | 2010-03-04 | 2020-01-31 | Macrogenics, Inc. | Przeciwciała reaktywne wobec b7-h3, ich immunologicznie czynne fragmenty i ich zastosowania |
TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
MX353144B (es) | 2010-04-20 | 2017-12-20 | Genmab As | Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas. |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
AU2011257121A1 (en) | 2010-05-27 | 2013-01-10 | Genmab A/S | Monoclonal antibodies against HER2 |
EP2606064B1 (en) | 2010-08-16 | 2015-02-25 | NovImmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
CN103068847B (zh) | 2010-08-24 | 2019-05-07 | 罗切格利卡特公司 | 可活化的双特异性抗体 |
RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
EP2771364B1 (en) | 2011-10-27 | 2019-05-22 | Genmab A/S | Production of heterodimeric proteins |
SG10201913376XA (en) | 2012-04-20 | 2020-02-27 | Merus Nv | Methods and means for the production of ig-like molecules |
AU2013285355A1 (en) | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
DK2869845T3 (da) | 2012-07-06 | 2019-12-09 | Genmab Bv | Dimert protein med tredobbelte mutationer |
DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
SG11201507037XA (en) | 2013-03-14 | 2015-10-29 | Genentech Inc | Anti-b7-h4 antibodies and immunoconjugates |
AU2014286116A1 (en) | 2013-07-05 | 2016-02-04 | Genmab A/S | Humanized or chimeric CD3 antibodies |
JP6853176B2 (ja) * | 2015-01-08 | 2021-03-31 | ゲンマブ エー/エス | Cd3およびcd20に対する二重特異性抗体 |
EA201890305A1 (ru) | 2015-07-15 | 2018-07-31 | Генмаб А/С | Гуманизированные или химерные cd3-антитела |
KR102346988B1 (ko) * | 2016-07-26 | 2022-01-03 | 시즈오카켄 | 항 b7-h4 항체 |
MX2020002076A (es) | 2017-08-25 | 2020-03-24 | Five Prime Therapeutics Inc | Anticuerpos de b7-h4 y metodos para usarlos. |
PE20230444A1 (es) | 2020-03-18 | 2023-03-08 | Genmab As | Anticuerpos |
-
2021
- 2021-03-17 PE PE2022001942A patent/PE20230444A1/es unknown
- 2021-03-17 KR KR1020227035619A patent/KR20220154757A/ko unknown
- 2021-03-17 CN CN202180022020.7A patent/CN115298221A/zh active Pending
- 2021-03-17 JP JP2022555952A patent/JP2023517753A/ja active Pending
- 2021-03-17 TW TW110109575A patent/TW202200624A/zh unknown
- 2021-03-17 IL IL296362A patent/IL296362A/en unknown
- 2021-03-17 AU AU2021236906A patent/AU2021236906A1/en active Pending
- 2021-03-17 CR CR20220521A patent/CR20220521A/es unknown
- 2021-03-17 BR BR112022015572A patent/BR112022015572A2/pt unknown
- 2021-03-17 CA CA3168613A patent/CA3168613A1/en active Pending
- 2021-03-17 WO PCT/EP2021/056879 patent/WO2021185934A1/en active Application Filing
- 2021-03-17 MX MX2022009936A patent/MX2022009936A/es unknown
- 2021-03-17 AR ARP210100670A patent/AR121599A1/es unknown
- 2021-03-17 EP EP21711911.4A patent/EP4121456A1/en active Pending
- 2021-03-17 US US17/204,604 patent/US20210292418A1/en active Pending
- 2021-10-05 US US17/494,545 patent/US11261254B1/en active Active
-
2022
- 2022-03-15 US US17/695,550 patent/US20220324980A1/en active Pending
- 2022-09-09 DO DO2022000181A patent/DOP2022000181A/es unknown
- 2022-09-13 CL CL2022002494A patent/CL2022002494A1/es unknown
- 2022-10-14 CO CONC2022/0014603A patent/CO2022014603A2/es unknown
- 2022-10-17 EC ECSENADI202280714A patent/ECSP22080714A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023517753A (ja) | 2023-04-26 |
TW202200624A (zh) | 2022-01-01 |
KR20220154757A (ko) | 2022-11-22 |
CN115298221A (zh) | 2022-11-04 |
US20220048999A1 (en) | 2022-02-17 |
BR112022015572A2 (pt) | 2022-09-27 |
IL296362A (en) | 2022-11-01 |
AU2021236906A1 (en) | 2022-08-18 |
US20210292418A1 (en) | 2021-09-23 |
CO2022014603A2 (es) | 2023-02-16 |
US20220324980A1 (en) | 2022-10-13 |
DOP2022000181A (es) | 2022-10-16 |
EP4121456A1 (en) | 2023-01-25 |
WO2021185934A1 (en) | 2021-09-23 |
CR20220521A (es) | 2023-01-23 |
AR121599A1 (es) | 2022-06-22 |
MX2022009936A (es) | 2022-09-12 |
US11261254B1 (en) | 2022-03-01 |
ECSP22080714A (es) | 2022-11-30 |
CL2022002494A1 (es) | 2023-03-03 |
CA3168613A1 (en) | 2021-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20230444A1 (es) | Anticuerpos | |
CO2019003923A2 (es) | Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos | |
PE20221262A1 (es) | Anticuerpos terapeuticos y sus usos | |
CL2021002645A1 (es) | Anticuerpos anti-muc16-cd3 biespecíficos y conjugados anti-muc16-fármacos. (divisional de solicitud 201900726) | |
EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
PE20210321A1 (es) | Anticuerpos biespecificos contra dll3-cd3 | |
CL2021000131A1 (es) | Anticuerpos anti-bcma x anti-cd3 biespecíficos y usos de estos. | |
DOP2017000160A (es) | Anticuerpos anti-CD3, anticuerpos anti-CD123 y anticuerpos biespecíficos que se unen específicamente a CD3 y/o CD123 | |
PE20220278A1 (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d | |
PE20212205A1 (es) | Proteinas de union condicionalmente activadas restringidas | |
PE20231511A1 (es) | Moleculas biespecificas de celulas t activadas por proteasas que se unen especificamente al receptor 1 de folato (folr1) y cd3 | |
PE20090329A1 (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
PE20230616A1 (es) | Anticuerpos que se unen a cd3 y folr1 | |
AR070141A1 (es) | Anticuerpos humanizados especificos para el factor von willebrand | |
PE20221465A1 (es) | Anticuerpos anti-trem2 y metodos para utilizarlos | |
PH12020551153A1 (en) | Antibodies specific for cd70 and their uses | |
BR112016007232A2 (pt) | anticorpos anti-epcam e métodos de uso | |
MX2021012962A (es) | Anticuerpo monoclonal que se une especificamente a gitr. | |
PE20230835A1 (es) | Anticuerpos que se unen a cd3 | |
PE20231552A1 (es) | Anticuerpos biespecificos para linfocitos t activados por proteasa | |
CR20200391A (es) | Moléculas biespecíficas de unión al antígeno y métodos de uso | |
MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
MX2022003833A (es) | Anticuerpos anti-kir3dl3 y sus usos. |